-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the global Phase 3 RAINBOW study, ramucirumab + paclitaxel significantly improved the overall survival of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma compared with placebo + paclitaxel
Stomach cancer
RAINBOW-Asia is a randomized, double-blind, placebo-controlled phase 3 trial conducted in 32 medical centers in China, Malaysia, the Philippines, and Thailand.
Survival prognosis in both groups
Survival prognosis in both groupsFrom March 2, 2017 to June 30, 2020, a total of 440 patients were randomly assigned to the ramucirumab group (n=294) or placebo group (n=146)
The median progression-free survival of ramucirumab and placebo groups were 4.
The occurrence of adverse events
The occurrence of adverse eventsThe most common adverse events of grade 3 and above requiring emergency treatment are decreased neutrophil count (54% vs 39%), decreased white blood cell count (43% vs 29%), anemia (16% vs 17%), high Blood pressure (7% vs 6%) and febrile neutropenia (6% vs <1%)
In summary, the results of this study are consistent with those of the RAINBOW study, supporting the use of ramucirumab combined with paclitaxel as a second-line treatment for patients with advanced gastric cancer or GEJ adenocarcinoma (mainly Chinese patients)
The results of this study are consistent with those of the RAINBOW study and support the use of ramucirumab combined with paclitaxel as a second-line treatment for patients with advanced gastric cancer or GEJ adenocarcinoma (mainly Chinese patients)
Original source:
Rui-Hua Xu, et al.
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
in this message
